Group 1 - The core viewpoint of the article highlights the recent stock performance of CSPC Pharmaceutical Group, which saw a decline of 2.03% to HKD 10.15 per share, with a trading volume of HKD 374 million [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, focusing on innovative drugs as its core development strategy [1] - The company has a strong product portfolio in therapeutic areas such as neurological diseases, oncology, anti-infection, and cardiovascular diseases, supported by an international R&D team [1] Group 2 - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [2]
石药集团(01093)下跌2.03%，报10.15元/股